GlycoMimetics To Host Leader Event To Review Results From Pivotal Phase 3 Study Of Uproleselan In Relapsed/Refractory Acute Myeloid Leukemia On June 4, 2024
Portfolio Pulse from Benzinga Newsdesk
GlycoMimetics, Inc. (NASDAQ:GLYC) will host a key opinion leader event on June 4, 2024, to review results from its pivotal Phase 3 study of uproleselan in relapsed/refractory acute myeloid leukemia. The event will feature Dr. Daniel DeAngelo from Harvard Medical School.
May 29, 2024 | 8:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
GlycoMimetics will host an event to review pivotal Phase 3 study results of uproleselan in relapsed/refractory AML, featuring Dr. Daniel DeAngelo from Harvard Medical School.
The announcement of a key opinion leader event to discuss pivotal Phase 3 study results is likely to generate significant interest and potentially positive sentiment among investors, leading to a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100